News & Updates

Prophylactic azithromycin helps prevent asthma attacks

26 Aug 2024 by

Prophylactic use of azithromycin was associated with significantly fewer infections and hospitalizations in patients with asthma, according to real-world data presented during the CHEST 2021 Congress.

Prophylactic azithromycin helps prevent asthma attacks

26 Aug 2024

COVID-19 infection ups CV risk in people living with HIV

26 Aug 2024 by

People living with HIV (PLWH) who were diagnosed with COVID-19 had a 35-percent higher risk of a major cardiovascular (CV) event in the following year than PLWH without COVID in a Spanish study.

COVID-19 infection ups CV risk in people living with HIV

26 Aug 2024

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

26 Aug 2024 by

Viral suppression is maintained through 48 weeks in adults with HIV-1 harbouring drug resistance mutations, who switched to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination pill from a boosted protease inhibitor (bPI) therapy, according to recent data from the phase IV open-label PIBIK trial.

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

26 Aug 2024

Lefamulin: An alternative to moxifloxacin in pneumonia treatment?

25 Aug 2024 by

The pleuromutilin inhibitor lefamulin shows similarly high efficacy as moxifloxacin (a standard fluoroquinolone therapy for clearing bacterial pneumonia) regardless of whether it was for unilobar or multilobar pneumonia, according to pooled data of the LEAP* 1 and 2 studies.

Lefamulin: An alternative to moxifloxacin in pneumonia treatment?

25 Aug 2024

[JM test]Interventional oncology faces trials on road to guideline inclusion

23 Aug 2024 by

Despite the known effectiveness of various interventional oncology (IO) procedures in many areas of cancer treatment, many continue to be overlooked in treatment guidelines due to evidence issues, say experts.

[JM test]Interventional oncology faces trials on road to guideline inclusion

23 Aug 2024

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

22 Aug 2024 by

Systemic therapy plays a central role in the management of unresectable hepatocellular carcinoma (HCC). In this rapidly developing therapy area, recent clinical trials are redefining systemic treatments, including multiple kinase inhibitors (MKI). During the recent Gastro Lunch and Learn sessions sponsored by Eisai, Dr David Tai and Dr Yong Wei Peng discussed the evidence behind MKIs such as lenvatinib (Lenvima^®) in the treatment of unresectable HCC through a case-based approach.

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

22 Aug 2024

Treating type 2 diabetes mellitus with G.R.A.C.E.

22 Aug 2024

A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI^®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.

Treating type 2 diabetes mellitus with G.R.A.C.E.

22 Aug 2024

[PD TEST]Sequential therapy beefs up bone density in women with anorexia

22 Aug 2024 by

Administering recombinant human insulin-like growth hormone-1 (rhIGF-1) for 6 months followed by risedronate for another 6 months helps improve bone mineral density (BMD) at the spine in women with anorexia nervosa, according to a study.

[PD TEST]Sequential therapy beefs up bone density in women with anorexia

22 Aug 2024

[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata

19 Aug 2024 by

Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).

[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata

19 Aug 2024

Digital Health and Telemedicine

16 Aug 2024

Exploring the rise of telehealth services, digital health records, and remote patient monitoring, and how these technologies are transforming healthcare delivery.

Digital Health and Telemedicine

16 Aug 2024

News & Updates

Filter by Specialty:

Specialty:

Prophylactic azithromycin helps prevent asthma attacks

Prophylactic azithromycin helps prevent asthma attacks

COVID-19 infection ups CV risk in people living with HIV

COVID-19 infection ups CV risk in people living with HIV

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

PIBIK: Switching to B/F/TAF maintains HIV suppression through 48 weeks

Lefamulin: An alternative to moxifloxacin in pneumonia treatment?

Lefamulin: An alternative to moxifloxacin in pneumonia treatment?

[JM test]Interventional oncology faces trials on road to guideline inclusion

[JM test]Interventional oncology faces trials on road to guideline inclusion

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

Response redefined with the power of lenvatinib in first-line unresectable HCC therapy

Treating type 2 diabetes mellitus with G.R.A.C.E.

Treating type 2 diabetes mellitus with G.R.A.C.E.

[PD TEST]Sequential therapy beefs up bone density in women with anorexia

[PD TEST]Sequential therapy beefs up bone density in women with anorexia

[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata

[MK TEST DO NOT TOUCH] Deuruxolitinib helps restore crowning glory in alopecia areata

Digital Health and Telemedicine

Digital Health and Telemedicine